Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis
Sponsor: Arena Pharmaceuticals
Terminated
Sponsor decision
A PHASE2 clinical study on Primary Biliary Cholangitis, this trial is terminated or withdrawn. The trial is conducted by Arena Pharmaceuticals and has accumulated 13 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Jun 2019 — Mar 2020 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Dec 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Arena Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .